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Decisions about when to start or switch a therapy often depend on the frequency
with which individuals are monitored or tested. For example, the optimal time to
switch antiretroviral therapy depends on the frequency with which HIV-positive
individuals have HIV RNA measured. This paper describes an approach to use
observational data for the comparison of joint monitoring and treatment strate-
gies and applies the method to a clinically relevant question in HIV research:
when can monitoring frequency be decreased and when should individuals
switch from a first-line treatment regimen to a new regimen?
We outline the target trial that would compare the dynamic strategies of inter-
est and then describe how to emulate it using data from HIV-positive individuals
included in the HIV-CAUSAL Collaboration and the Centers for AIDS Research
Network of Integrated Clinical Systems. When, as in our example, few individ-
uals follow the dynamic strategies of interest over long periods of follow-up, we
describe how to leverage an additional assumption: no direct effect of monitor-
ing on the outcome of interest. We compare our results with and without the “no
direct effect” assumption. We found little differences on survival and AIDS-free
survival between strategies where monitoring frequency was decreased at a
CD4 threshold of 350 cells/μl compared with 500 cells/μl and where treat-
ment was switched at an HIV-RNA threshold of 1000 copies/ml compared
with 200 copies/ml. The “no direct effect” assumption resulted in efficiency
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1 INTRODUCTION
Many clinical guidelines recommend starting, stopping, or switching a therapy when a clinical marker crosses a certain
threshold. For example, some guidelines recommend that adults initiate statin therapy if LDL cholesterol is greater than
190 mg/dL,1 and others recommend that HIV-positive individuals switch treatment (antiretroviral therapy [ART]) if HIV
RNA is greater than 500 copies/ml.2 These guidelines are examples of dynamic strategies because the decision to start or
switch therapy depends on an individual's time-varying covariates (LDL cholesterol or HIV RNA).
When randomized trials are not available to inform guidelines, observational data can be used to try to emulate a
hypothetical randomized trial, ie, a target trial,3 of dynamic strategies. For example, previous observational analyses have
emulated target trials in which HIV-positive individuals were assigned to different treatment initiation and switching
strategies.4-10 Adjustment for measured time-varying confounders was achieved via inverse probability weighting4,6 or the
parametric g-formula.8-10
However, recommendations about when to start or switch a therapy generally depend on the frequency with which
individuals are monitored or tested.11 For example, the optimal time to switch therapy may be the first time HIV RNA
crosses above 500 copies/ml if HIV-positive individuals are monitored every 6 months but at a different threshold, ie,
lower than 500 copies/ml, if individuals were monitored every 12 months. Therefore, clinical guidelines for starting or
switching a treatment based on the results of a test need to specify both the frequency of monitoring/testing and the
threshold at which treatment is started or switched.
In this paper, we extend the methodology to emulate a target trial of joint monitoring and treatment strategies using
observational data and describe how to leverage an additional assumption: no effect of monitoring on the outcome
except through aiding decisions concerning when to switch ART.11 Exploiting this “no direct effect” assumption may
drastically decrease the estimates' variance without requiring additional modeling assumptions. Section 2 outlines the
key components of the target trial and how to emulate it using observational data from HIV-positive individuals. In
Section 3, we describe how to estimate the per-protocol effect, first in the target trial and then using observational data.
Section 4 introduces the “no direct effect” assumption and compares the efficiency of the results estimated with and
without the additional assumption.
2 SPECIFICATION AND EMULATION OF THE TARGET TRIAL
Table 1 summarizes the key components of the protocol of the target trial in which participants are randomly assigned
to one of four joint monitoring and treatment strategies, based loosely on current clinical guidelines.2,15-17 The goal of the
trial is to determine the joint strategy with the greatest 5-year survival and AIDS-free survival for HIV-positive individuals
who achieve virologic suppression within 12 months of initiating an eligible ART regimen.
Strategy (1): CD4 threshold 350/tight control. In this strategy, CD4 cell count and HIV RNA are monitored every
3-6 months when CD4 is below a threshold of 350 cells/μl and every 9-12 months when CD4 is above the threshold, and
individuals switch treatment within 3 months of HIV RNA crossing above 200 copies/ml (tight control) and do not switch
again.
Strategy (2): CD4 threshold 350/loose control. This strategy is the same as (1) except that the HIV-RNA threshold is 1000
copies/ml (loose control).
Strategy (3): CD4 threshold 500/tight control. This strategy is the same as (1) except that the CD4 cell count threshold is
500 cells/μl.
Strategy (4): CD4 threshold 500/loose control. This strategy is the same as (3) except that the HIV-RNA threshold is 1000
copies/ml.
All four strategies further require individuals to be monitored every 3-6 months when HIV RNA > 200 copies/ml or
after diagnosis of an AIDS-defining illness (Figure 1).
Any treatment change was classified as a nonswitch, ineligible switch, or switch (see Table D1). For example, a change
from one protease inhibitor–based regimen to another protease inhibitor–based regimen was not considered a switch,
whereas a change from a protease inhibitor–based regimen to an integrase inhibitor–based regimen was considered a
switch. Any changes to monotherapy or dual therapy or stopping therapy altogether were considered ineligible switches
as they are not consistent with current guidelines.7 The switching thresholds were based on current clinical guidelines
and to maximize the number of individuals following distinct strategies (in practice, switching also occurs for reasons
other than treatment failure).
TABLE 1 Key components of the protocol of the target trial of joint monitoring and treatment strategies
Component Target Trial Emulation Using Observational Data
Eligibility (1) Confirmed virologic suppression (two consecutive Same, except pregnancy information
criteria HIV RNA ≤ 200 copies/ml) within 12 months of is not available for all individuals.
initiating an eligible treatment regimen in 2000 or
later while remaining on an eligible treatment
regimen (Table D1)
(2) 18 years or older, no history of AIDS-defining
illness,12 a CD4 cell count
measurement, no pregnancy
Joint (1) CD4 threshold 350/tight control: CD4 cell count Same, except changes to new
monitoring and HIV RNA are monitored every 3-6 months regimens lasting fewer than 14 days
and when CD4 is below a threshold of 350 cells/μl and were not considered treatment
treatment every 9-12 months when CD4 is above the threshold, switches and person-time was
strategies and individuals switch treatment (Table D1) within assigned to the previous regimen of
3 months of HIV RNA crossing above 200 copies/ml duration 14 days or longer (sensitivity
(2) CD4 threshold 350/loose control: same as (1) analyses with periods other than 14
except that the HIV-RNA threshold is 1000 did not materially change the results).
copies/ml
(3) CD4 threshold 500/tight control: same as (1)
except that the CD4 cell count threshold is 500
cells/μl
(4) CD4 threshold 500/loose control: same as (3)
except that the HIV-RNA threshold is 1000
copies/ml
All four strategies further require individuals to be
monitored once every 3-6 months (±1 month) when
HIV RNA > 200 copies/ml or after diagnosis of an
AIDS-defining illness. Individuals cannot switch
after the initial treatment switch.
Outcomes (1) All-cause mortality Same. The date of death was
(2) Combined endpoint of AIDS-defining illness or identified using a combination of
death national and local mortality registries
and clinical records, as described
elsewhere,13,14 and
AIDS-defining illnesses were
ascertained by the treating physicians.
Follow-up Individuals are followed from baseline (confirmed Same, except that the cohort-specific
period virologic suppression while otherwise eligible, when administrative end of follow-up may
randomization occurs) until the event of interest, be less than 5 years from baseline and
pregnancy, loss to follow-up (12 months after the pregnancy information is not available
most recent laboratory measurement), or 5 years for all individuals.
of follow-up, whichever occurred earlier.
Causal (1) Intention-to-treat effect Per-protocol effect only. Since
contrast(s) of (2) Per-protocol effect, ie, the effect that would have all individuals included in our study
interest been observed if all individuals were monitored and had data consistent with each of the
switched treatment as indicated by their four joint monitoring and treatment
randomization arm strategies at baseline, an intention-to-
treat analysis would compare groups
consisting of the same individuals.
Analysis (1) Intention-to-treat analysis Same per-protocol analysis, except that
plan (2) Per-protocol analysis (see text) individuals were replicated because their
baseline data were consistent with more
than one strategy.
We consider two clinical endpoints: all-cause mortality and a combined endpoint of AIDS-defining illness or death.
Our goal is to estimate the per-protocol effect, that is, the effect that would have been observed if all individuals were
monitored and switched treatment as indicated by their assigned strategy.
We emulated this target trial using observational data from two collaborations of prospective studies from high-income
countries. The HIV-CAUSAL Collaboration includes prospective cohort studies from Europe and the Americas.13 The
Strategy 1: Threshold=350 cells/  l; Level=200 copies/ml 
Strategy 2: Threshold=350 cells/  l; Level=1000 copies/ml
Strategy 3: Threshold=500 cells/  l; Level=200 copies/ml
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FIGURE 1 Schematic of four dynamic monitoring and treatment strategies to be followed at each time t of follow-up. By considering the
combinations of two CD4 cell count thresholds (350 and 500 cells/μl) and two HIV-RNA levels (200 and 1000 copies/ml), four strategies are
defined
individual cohort studies are FHDH-ANRSC04 (France), ANRS PRIMO (France), ANRS SEROCO (France), ANRS
CO3-Aquitaine (France), UK CHIC (United Kingdom), UK Register of HIV Seroconverts (United Kingdom), ATHENA
(the Netherlands), SHCS (Switzerland), PISCIS (Spain), CoRIS/CoRIS-MD (Spain), GEMES (Spain), VACS (United
States), AMACS (Greece), IPEC (Brazil), and SAC (Canada). The Center for AIDS Research Network of Integrated Clin-
ical Systems (CNICS) contains clinical data from inpatient and outpatient encounters of HIV-positive individuals at
eight US sites: Case Western Reserve University, Fenway Community Health Clinic, Johns Hopkins University, University
of Alabama at Birmingham, University of California at San Diego, University of California at San Francisco, University
of North Carolina, and University of Washington.14 All cohorts included in the HIV-CAUSAL and CNICS Collaborations
were assembled prospectively and are based on data collected for clinical purposes.
To emulate the target trial, we identified HIV-positive individuals who met the eligibility criteria, classified them into
the four strategies (see below), and followed them until the event of interest, pregnancy, loss to follow-up (12 months after
the most recent laboratory measurement), 5 years of follow-up, or the cohort-specific administrative end of follow-up,
whichever occurred earlier. To allow more individuals to follow each strategy over time, our primary analysis included
an additional month before and after each monitoring window (eg, 3-6 ± 1), so that the monitoring grace period
was 5 months. In the next sections, we describe how to estimate the per-protocol effect in the target trial and using
observational data.
3 ESTIMATING THE PER-PROTOCOL EFFECT
3.1 Specification of per-protocol analysis in the target trial
Eligible individuals are randomized at enrollment in the trial to one of the four joint monitoring and treatment strategies.
We define the per-protocol effect as the difference in 5-year survival and AIDS-free survival between the four strategies
if all individuals have followed their assigned strategies as indicated in the protocol of the target trial. We describe a
three-step procedure to estimate the per-protocol effect in the target trial.
First, censor individuals when they deviate from their assigned strategy. Specifically, censor individuals when they are
monitored sooner than indicated by their strategy, when they are not monitored soon enough, when they change treat-
ment sooner than indicated by their strategy, when they have not switched at the end of the 3-month treatment-switching
grace period, when they switch treatment again after their initial treatment switch, when only a CD4 cell count or
HIV-RNA measurement is recorded (uneven monitoring), or when they switch to an ineligible treatment regimen
(Figure 2).
Second, fit a discrete-time hazards model and use its predicted values to estimate standardized survival and AIDS-free
survival curves.6,18,19 For example, the discrete-time hazard at each month t can be estimated by fitting a pooled logis-
tic model such as logit Pr(Dt+1 = 1|Dt = 0,Ct = 0,X ,V ) = 𝜃0 + h (t) + 𝜃′1V + 𝜃2X350−tight control + 𝜃3X350−loose control +
𝜃4X500−loose control + 𝜃′5X350−tight controlh (t) + 𝜃
′
6X350−loose controlh (t) + 𝜃
′
7X500−loose controlh (t), where 𝜃0 + h(t) is a time-varying
intercept, with h(t) defined as a restricted cubic spline for follow-up time (four knots at 1, 6, 12, and 24 months), Dt is an
indicator for developing the outcome by month t (1: yes, 0: no), V is a vector of baseline prognostic factors that predict
adherence, the X's are indicators for the corresponding strategy (1: yes, 0: no) with the strategy CD4 threshold 500/tight
control as the reference, and Ct = 0 is an indicator for the remaining uncensored through t. We use prime notation to
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FIGURE 2 Flow diagram for the eligibility criteria and censoring process (Center for AIDS Research Network of Integrated Clinical
Systems and HIV-CAUSAL Collaboration, 2000-2015)
denote vectors since V is a vector of baseline covariates and h(t) includes three covariates. We include product terms
between h(t) and the X's so that the estimated hazard ratios can vary over time. The model uses a smooth function to
combine information from each strategy, producing more stable estimates than a nonparametric estimate of the survival
function (eg, Kaplan-Meier).6 This model adjusts for baseline (time-fixed) prognostic factors, but not for post-baseline
(time-varying) factors because the inclusion of post-baseline covariates in the model for the outcome may introduce
selection bias.20
Third, estimate inverse probability (IP) weights to adjust for post-baseline prognostic factors. To describe the weights,
we need to introduce some additional notation. Let At = 2 indicate that the individual switches to an eligible regimen at
time t, At = 1 indicate that the individual switches to an ineligible regimen during time t, and At = 0 indicate that the
individual does not switch treatment during time t. Let Nt = 2 indicate that the individual has both CD4 cell count and
HIV-RNA measurements during time t, Nt = 1 indicate that the individual has either a CD4 cell count or an HIV-RNA
measurement during time t but not both, and Nt = 0 indicate that the individual has neither a CD4 cell count nor an
HIV-RNA measurement during time t. We use overbars to denote the history of a time-dependent variable: Nt is the
individual's monitoring history through time t, Āt is the individual treatment-switching history through time t, and L̄t is
the individual time-varying covariate history through time t.







Ck = 0|Ck−1 = 0,Dk = 0,X = x, L̄k,Nk, Āk−1
) .
Pr(Ck = 0|Ck−1 = 0,Dk = 0,X = x, L̄k,Nk, Āk−1) is equal to 𝑓 (Ak|Āk−1,Dk = 0, L̄k,Nk) before and after the
treatment-switching grace period, where 𝑓 (Ak|Āk−1,Dk = 0, L̄k,Nk) is the conditional probability density function
𝑓Ak ∣Āk−1,Dk=0,L̄k ,Nk
(ak|ak−1, dk = 0, lk,nk) with (ak|ak−1, dk = 0, lk,nk) evaluated at the random argument (Ak|Āk−1,Dk =
0, L̄k,Nk) and is equal to 1 − Pr(Ak = 1|Āk−1,Dk = 0, L̄k,Nk) during the treatment-switching grace period.6,21
We estimate Pr(Ak = ak|Āk−1,Dk = 0, L̄k,Nk) via a pooled multinomial logistic regression model fit in the original
data. Alternatively, we could fit two nested logistic models: a model for ineligible treatment switching and a model for an
eligible treatment switch (versus no switch) conditional on not having an ineligible treatment switch (Appendix A).
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) .
Pr(Ck = 0|Ck−1 = 0,Dk = 0,X = x, L̄k−1,Nk−1, Āk−1) is equal to 𝑓 (Nk|Nk−1,Dk = 0, L̄k−1, Āk−1) before and
after the monitoring grace period, where 𝑓 (Nk|Nk−1,Dk = 0, L̄k−1, Āk−1) is the conditional probability mass func-
tion 𝑓Nk ∣Nk−1,Dk=0,L̄k−1,Āk−1 (nk|nk−1, dk = 0, lk−1, ak−1) with (nk|nk−1, dk = 0, lk−1, ak−1) evaluated at the random argument
(Nk|Nk−1,Dk = 0, L̄k−1, Āk−1) and is equal to 1 − Pr(Nk = 1|Nk−1,Dk = 0, L̄k−1, Āk−1) during the monitoring grace period.
We estimate Pr(Nk = nk|Nk−1,Dk = 0, L̄k−1, Āk−1) via a pooled multinomial logistic model fit in the original data. Alter-
natively, we could fit two nested logistic models: a model for uneven monitoring (only a CD4 cell count or HIV-RNA
measurement is recorded) and a model for CD4 and RNA monitoring (versus no monitoring) conditional on not having
uneven monitoring (Appendix A).
All models include a time-varying intercept; monitoring history Nk summarized by the proportion of months of
follow-up from baseline to time k with a CD4 cell count measurement (restricted cubic splines with three knots at 0.2,
0.3, and 0.5), the proportion of months of follow-up from baseline to time k with an RNA measurement (restricted cubic
splines with three knots at 0.2, 0.3, and 0.5), months between time k and the last CD4 cell count measurement (restricted
cubic splines with three knots at 1, 4, and 7), and months between time k and the last RNA measurement (restricted cubic
splines with three knots at 1, 4, and 7); treatment-switching history Āk summarized by whether an individual switched
treatment from baseline to time k (yes/no) and the number of months between time k and the treatment switch (restricted
cubic splines with three knots at 0, 6, and 12); and covariate history L̄k summarized by V and Lk, which includes the most
recently recorded values of CD4 cell count (restricted cubic splines with five knots at 200, 350, 500, 650, and 1000 cells/μl),
HIV RNA (≤200, 201-999, 1000-9999, ≥10 000 copies/ml), and diagnosis of an AIDS-defining illness (when the outcome
was all-cause mortality) at time k.
The nonstabilized IP weight Wt for each person-month is the product of the treatment-switching weight and the mon-
itoring weight Wt = W At ∗ W
N
t . We truncate the estimated weights Wt at the 99th percentile to protect against potential
model misspecification and near violations of positivity.
Under the assumptions of sequential exchangeability, positivity, and consistency for monitoring and treatment switch-
ing conditional on the measured time-fixed and time-varying covariates,11 the parameters of the IP-weighted discrete-time
hazards model consistently estimate the parameters of a dynamic marginal structural discrete-time hazards model, ie,
logit Pr
(
Dxt+1 = 1|Dxt = 0,V) = 𝛽0 + h (t) + 𝛽′1V + 𝛽2x350−tight control + 𝛽3x350−loose control
+ 𝛽4x500−loose control + 𝛽′5x350−tight controlh (t) + 𝛽
′
6x350−loose controlh (t)
+ 𝛽′7x500−loose controlh (t) ,
where Dxt is, for each individual, a (counterfactual) indicator for developing the outcome by month t (1: yes, 0: no) under
strategy X = x for monitoring and treatment. The validity of this procedure also requires no misspecification of the models
used to estimate the weights and of the discrete-time hazards model.
The nonstabilized IP weights defined above imply strategies under which individuals who were not monitored or did
not switch during the corresponding grace period are forced to be monitored or switch treatment at the end of the grace
period.6 Since this can lead to unstable estimates and may not be consistent with clinical practice, we also consider IP
weights that estimate strategies under which individuals are monitored with a uniform probability during the monitoring
grace period and switch treatment with a uniform probability during the treatment-switching grace period.6 Appendix A
shows the contributions to the monitoring and treatment-switching weights at different time points for both the non-
stabilized and uniform IP weights. We used nonparametric bootstrapping with 500 samples to compute 95% confidence
intervals around our estimates.
Even if the data on monitoring and treatment strategy assignment had been inadvertently erased from the analysis file
in the target trial, one can still construct consistent estimators of the per-protocol effects under exchangeability, consis-
tency, and positivity. In fact, Robins shows that the most efficient estimator of the per-protocol effect ignores data on
assignment even when available.22 The following section describes estimators that ignore data on assignment to emulate
the per-protocol analysis of a target trial using observational data.
3.2 Emulation of the per-protocol analysis using observational data
The observational per-protocol analysis is the same as described above for the target trial except that data on monitoring
and treatment strategy assignment are absent as no such assignment occurred. In fact, an individual's data at baseline may
be consistent with more than one of the four strategies of interest. As previously described in detail,6,7,23 we solved this
problem by creating an expanded data set with four exact replicates of each individual (one per strategy), each following
one of the strategies of interest. We censored each replicate, as described above, when the individual's data were no longer
consistent with the strategy assigned to the replicate. Appendix B describes data for three hypothetical individuals and
the strategies they followed over 24 months of follow-up time. To estimate the per-protocol effect, we used the same
IP-weighted pooled logistic model described for the target trial, except that we fitted the model to the expanded data set.
The models for the weights were fit in the original unexpanded data set.
Data from each participating study can be requested from the sponsoring institution in accordance with the applicable
laws or regulations in each country. SAS programs are available at https://www.hsph.harvard.edu/causal/hiv.
3.3 Data analysis results
In our analysis, 41 724 individuals met the eligibility criteria and were included. After 2 years of follow-up, 1006 indi-
viduals were following the CD4 threshold 350/tight control strategy, 2634 individuals were following the CD4 threshold
500/tight control strategy, 1050 individuals were following the CD4 threshold 350/loose control strategy, and 2741 individ-
uals were following the CD4 threshold 500/loose control strategy. After 5 years of follow-up, these numbers were 45, 152,
47, and 164, respectively (Figure 3). Over the 5-year follow-up, there were 455 deaths and 1151 cases of AIDS-defining ill-
ness or death (Table 2). The median (interquartile range) time from baseline to death among individuals who died was 5
(2, 10) months. Figure 4 plots the estimated 5-year survival and 5-year AIDS-free survival. Compared with the CD4 thresh-
old 500/tight control strategy, the 5-year survival difference was 0.01 (−0.01, 0.04) for the CD4 threshold 350/tight control
strategy, 0.01 (−0.02, 0.03) for the CD4 threshold 350/loose control strategy, and 0.00 (−0.01, 0.01) for the CD4 threshold
FIGURE 3 Number of replicates following each monitoring and treatment strategy over follow-up time, without (left) and with (right) the
“no direct effect” assumption (Center for AIDS Research Network of Integrated Clinical Systems and HIV-CAUSAL Collaboration, 2000-2015)
500/loose control. The 5-year AIDS-free survival difference was 0.00 (−0.02, 0.03) for the CD4 threshold 350/tight control
strategy, 0.00 (−0.02, 0.02) for the CD4 threshold 350/loose control strategy, and 0.00 (0.00, 0.01) for the CD4 threshold
500/loose control strategy, compared with the CD4 threshold 500/tight control strategy (Table 2).
4 ESTIMATING THE PER-PROTOCOL EFFECT WITH A “NO DIRECT
EFFECT” ASSUMPTION
In many settings, it can be argued that monitoring has no direct effect on the outcome except through aiding decisions
regarding switching treatment. For example, in our study, we can assume that having a laboratory measurement can only
affect the risk of AIDS or death by triggering treatment changes. More precisely, consider a target trial with two arms in
which both arms are assigned the same static treatment strategy but different monitoring strategies. Then, the “no direct
effect” assumption says that the two arms will have the same survival curves. By emulating this type of target trial with
observational data, it is, in principle, possible to test the “no direct effect” assumption under sequential exchangeability,
positivity, and consistency.24
Under the assumption of no direct effect of monitoring, measurements inconsistent with the monitoring strategy have
no effect on survival. Therefore, CD4 and HIV-RNA measurements at months not consistent with the monitoring strat-
egy can be ignored, and replicates need not be censored at those times. Because these individuals are not censored, we
will have more individuals continuing to follow the strategies of interest at any given time and, therefore, more precise
effect estimates. Under the “no direct effect” assumption, individuals can no longer be censored for being monitored too
frequently but can still be censored for not being monitored frequently enough. In fact, it is possible for the counter-
factual survival curve under a particular monitoring and treatment strategy to be identified under the “no direct effect”
assumption but to be unidentified (due to lack of positivity) without the assumption.11 For example, if all subjects in
the observational data were monitored every month, it would not be possible to identify the effect of any less frequent
monitoring strategy without the “no direct effect” assumption.
To implement the modified per-protocol analysis that incorporates the “no direct effect” assumption, we construct a
“no direct effect” version of the data using the following algorithm, formalized previously by Robins et al. Specifically, the
algorithm described next implements Equation 31 on page 4711, extended to allow for random treatment regimes as well
as random monitoring regimes11: (i) recode the monitoring indicator at each month t to 0 when an individual is monitored
at a time t inconsistent with his or her randomization arm's monitoring strategy (including when only CD4 cell count
or HIV RNA is measured), (ii) delete the CD4 cell count and HIV RNA recorded at month t whenever the monitoring


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FIGURE 4 Survival (left) and AIDS-free survival (right) under each monitoring and treatment strategy (Center for AIDS Research Network
of Integrated Clinical Systems and HIV-CAUSAL Collaboration, 2000-2015). The curves are standardized by the baseline covariates: sex, CD4
cell count (≤200, 201-350, 351-500, ≥501 cells/μl), years since HIV diagnosis (<1, 1 to 4, ≥5 years, unknown), race (white, black, other, or
unknown), geographic origin (N. America/W. Europe, Sub-Saharan Africa, other, unknown), acquisition group (heterosexual, homosexual,
or bisexual; injection drug use; other; or unknown), calendar year (restricted cubic splines with three knots at 2001, 2007, and 2011), age
(restricted cubic splines with three knots at 25, 39, and 60), cohort, and months from treatment initiation to virologic suppression (2-4, 5-8, ≥9)
time that individual is monitored (Appendix C). In this “no direct effect” data set, we then proceed to censor individuals
when they deviate from their assigned strategy and to estimate the survival and AIDS-free survival for each strategy, as
described above. To emulate the target trial using the observational data, we modify the expanded data set in the same
way to construct a “no direct effect” data set.
The algorithm described above can be extended to strategies with grace periods, which allows even more individuals
to follow the strategies of interest over a long period of time. The algorithm can be adapted to handle more than one
monitoring time during a grace period. To extend the algorithm, replicates monitored during the monitoring grace period
are further replicated, as a way of simulating monitoring trajectories where replicates are monitored at different times
during the monitoring grace period.11 Specifically, a replicate monitored during the grace period is cloned at the point of
their first measurement in the grace period into two new replicates 1t and 2t, where t denotes the time in the grace period
the cloning occurred. For replicate 1t, the new CD4 cell count and HIV-RNA measurements are revealed (recorded for
data analysis), and the replicate exits the monitoring grace period in the usual way. For replicate 2t, the new CD4 cell
count and HIV-RNA measurements are ignored, ie, the monitoring indicator is recoded to 0, the CD4 and HIV-RNA
measurements are deleted, the previous CD4 and RNA measurements are carried forward, and replicate 2t moves to the
next month of the grace period. Replicates are only censored if they are not monitored at least as frequently as required
by the strategy. As an example, replicate 2t will be censored if she receives no further monitoring during the grace period.
Appendix C describes the “no direct effect” data set for one hypothetical individual, first under strategies that require
individuals to be monitored exactly every 6 months if their CD4 cell count falls below the strategy's threshold and exactly
every 12 months otherwise and, second, under strategies with grace periods.








where N *(k) = 2 denotes times k when a replicate's CD4 and HIV-RNA values are revealed. The factors in the denomina-
tor of W Nt are 1 at all times when a replicate's CD4 and HIV-RNA values are not revealed (Appendix A).
11 The treatment
weights remain as before. Note that different replicates from a single person will have different weights. Below, we com-
pare the efficiency of the estimates with and without the “no direct effect” assumption when using uniform IP weights
(Table 2).
4.1 Data analysis results
After 5 years of follow-up, 28 997 individuals were following the CD4 threshold 350/tight control strategy, 24 901 individ-
uals were following the CD4 threshold 500/tight control strategy, 30 334 individuals were following the CD4 threshold
FIGURE 5 Survival (left) and AIDS-free survival (right) under each monitoring and treatment strategy with the “no direct effect”
assumption (Center for AIDS Research Network of Integrated Clinical Systems and HIV-CAUSAL Collaboration, 2000-2015). The curves
are standardized by the baseline covariates: sex, CD4 cell count (≤200, 201-350, 351-500, ≥501 cells/μl), years since HIV diagnosis (<1, 1 to 4,
≥5 years, unknown), race (white, black, other, or unknown), geographic origin (N. America/W. Europe, Sub-Saharan Africa, other,
unknown), acquisition group (heterosexual, homosexual, or bisexual; injection drug use; other; or unknown), calendar year (restricted cubic
splines with three knots at 2001, 2007, and 2011), age (restricted cubic splines with three knots at 25, 39, and 60), cohort, and months from
treatment initiation to virologic suppression (2-4, 5-8, ≥9)
350/loose control strategy, and 26 106 individuals were following the CD4 threshold 500/loose control strategy (Figure 3).
Over the 5-year follow-up, there were 5886 deaths and 9758 cases of AIDS-defining illness or death (Table 2). The median
(interquartile range) time to death among individuals who died was 14 (6, 28) months. Figure 5 plots the estimated 5-year
survival and 5-year AIDS-free survival. Compared with the CD4 threshold 500/tight control strategy, the 5-year survival
difference was 0.00 (0.00, 0.00) for the CD4 threshold 350/tight control strategy, 0.00 (0.00, 0.00) for the CD4 threshold
350/loose control strategy, and 0.00 (0.00, 0.00) for the CD4 threshold 500/loose control strategy. The 5-year AIDS-free
survival difference was 0.00 (0.00, 0.01) for the CD4 threshold 350/tight control strategy, 0.00 (−0.01, 0.01) for the CD4
threshold 350/loose control strategy, and 0.00 (−0.01, 0.00) for the CD4 threshold 500/loose control strategy, compared
with the CD4 threshold 500/tight control strategy (Table 2).
These estimates under the “no direct effect” assumption were more precise than those in the previous section. For
example, the standard errors for the 5-year survival difference estimates ranged from 0.0046 to 0.0131 without the “no
direct effect” assumption and from 0.0017 to 0.0019 with the “no direct effect” assumption, implying the ratio of the
effective sample size under the “no direct effect” assumption to that without the assumption ranging from 7 to 53.
5 DISCUSSION
This paper describes the use of observational data to emulate a target trial of joint monitoring and treatment strategies.
We applied the method to strategies for the management of HIV-positive individuals and found no differences on survival
and AIDS-free survival between strategies with monitoring at a CD4 threshold of 350 cells/μl compared with 500 cells/μl
and with treatment switching at an HIV-RNA threshold of 1000 copies/ml compared with 200 copies/ml.
Like for any other observational study, the validity of our estimates relies on the untestable assumption that the mea-
sured covariates were sufficient to adjust for confounding and selection bias. In our analysis, we adjusted for several joint
predictors of monitoring and the outcome as well as of treatment switching and the outcome. If physicians monitor indi-
viduals perceived to have lower adherence with greater frequency or make different decisions about treatment switching
based on perceived adherence, which we did not directly adjust for, this assumption may not hold. However, we were able
to adjust for several potential proxies of adherence, such as HIV RNA. In addition, our results could be biased if both the
monitoring frequency and survival vary by site. However, the monitoring frequency was similar between the countries
included in our analysis (data not shown).
One challenge in estimating the effect of complex treatment strategies using observational data is that few individuals
may have data consistent with the strategies of interest over an extended period of follow-up. We described how to ame-
liorate this by incorporating the often plausible assumption that monitoring has no direct effect on the outcome, except
through aiding decisions regarding when to switch treatment. The “no direct effect” assumption is advantageous because
it increases the number of individuals whose data are consistent with the strategies of interest and does not require addi-
tional modeling assumptions. In fact, our survival and AIDS-free survival estimates were similar with and without the
“no direct effect” assumption, but the estimates under the “no direct effect” assumption were more precise.
The “no direct effect” assumption may not be met if contact with health facilities improves outcomes through inter-
ventions that are either unrecorded in the database or not included as additional types of “treatments” in addition to
treatment switching. For example, if HIV care is integrated with other services like screening for cancer or cardiovascu-
lar disease, or if physicians use the results of a CD4 cell test to initiate treatments other than that under consideration
(eg, prophylaxis for opportunistic infections), the assumption may not hold (unless the strategy includes screening and/or
prophylaxis as additional “treatments”). However, under the strategies of interest, individuals with low CD4 cell counts
were monitored frequently (every 2-7 months), and so, few CD4 tests were deleted for these individuals when creating
the modified data set (in the analysis without the “no direct effect” assumption, only 4% of replicates censored for being
monitored too frequently had a CD4 cell count ≤200 cells/μl at the time they were censored).
The monitoring and treatment strategies in our primary analysis did not consider treatment switches after the initial
treatment switch. While strategies that allow arbitrary treatment switches would be more realistic,25 they are also com-
putationally harder to implement under the “no direct effect” assumption. In a sensitivity analysis without the “no direct
effect” assumption, we considered modified strategies that allowed treatment switches both before virologic failure and
after the initial treatment switch. This analysis yielded similar results (5-year survival difference compared with the CD4
threshold 500/tight control strategy: 0.01 (−0.01, 0.02) for the CD4 threshold 350/tight control strategy, 0.01 (−0.01, 0.04)
for the CD4 threshold 350/loose control strategy, and 0.01 (0.00, 0.01) for the CD4 threshold 500/loose control strategy).
The methods described in this paper can be extended to other joint monitoring and treatment strategies analyzed in
health research. The “no direct effect” assumption can be a useful tool in settings where individuals are monitored or
tested often, but inferences about less frequent monitoring or testing are desired. For example, this approach may be
particularly useful when data from a high-resource population with frequent testing are available but researchers want
to apply the estimates to a low-resource population with infrequent testing.11
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APPENDIX A
ESTIMATION OF IP WEIGHTS
We estimated Pr(Ak = ak|Āk−1,Dk = 0, L̄k,Nk) and Pr(Nk = nk|Nk−1,Dk = 0, L̄k−1, Āk−1) via pooled multinomial logistic
regression models. The corresponding contributions to the IP weights are outlined in Table A1.1 and A1.2. Equivalently,
we could have fit two sets of nested logistic models: a model for ineligible treatment switching Pr(Ak = 1|Āk−1,Dk =
0, L̄k,Nk) and a model for an eligible treatment switch (versus no switch) conditional on not having an ineligible treat-
ment switch Pr(Ak = 2|Ak ≠ 1, Āk−1,Dk = 0, L̄k,Nk). To estimate Pr(Nk = nk|Nk−1,Dk = 0, L̄k−1, Āk−1), we fit a model
for uneven monitoring Pr(Nk = 1|Nk−1,Dk = 0, L̄k−1, Āk−1) and a model for CD4 and RNA monitoring (versus no mon-
itoring) conditional on not having uneven monitoring Pr(Nk = 2|Nk ≠ 1|Nk−1,Dk = 0, L̄k−1, Āk−1). The corresponding
contributions to the IP weights are outlined in Table A2.1 and A2.2 The contributions to the IP weights outlined in
TABLE A1.1 Contribution to monitoring weights at different time points
Type of Weight
Time Point Monitor Nonstabilized Uniform Uniform w/NDE




1CD4 + RNA 0 (censored) 0 (censored)

































m, length of monitoring grace period in months; j, position in monitoring grace period (month)
N0: neither CD4 or RNA measured; N1: either CD4 or RNA measured but not both; N2: CD4 and RNA measured
Pr(N0), estimated by [Pr(Nk = 0|Nk−1,Dk = 0, L̄k−1, Āk−1)]
Pr(N1), estimated by [Pr(Nk = 1|Nk−1,Dk = 0, L̄k−1, Āk−1)]
Pr(N2), estimated by [Pr(Nk = 2|Nk−1,Dk = 0, L̄k−1, Āk−1)]
TABLE A1.2 Contribution to treatment switching weights at different time points
Type of Weight
Time Point Treatment Switch Nonstabilized Uniform Uniform w/NDE






































n, length of treatment-switching grace period in months
k, position in treatment-switching grace period (month)
A0: no switch; A1: switch to ineligible regimen; A2: switch to eligible regimen
Pr(A0), estimated by [Pr(Ak = 0|Āk−1,Dk = 0, L̄k ,Nk)]
Pr(A1), estimated by [Pr(Ak = 1|Āk−1,Dk = 0, L̄k ,Nk)]
Pr(A2), estimated by [Pr(Ak = 2|Āk−1,Dk = 0, L̄k ,Nk)]
*Corresponds to time before the first RNA> 200 copies/ml, as well as the time in the loose-control strategies where RNA> 200
but has not yet increased above 1000 copies/ml.
TABLE A2.1 Contribution to monitoring weights at different time points using nested models
Type of Weight
Time Point Monitor Nonstabilized Uniform Uniform w/NDE





CD4 + RNA 0 (censored) 0 (censored)
During grace period 0 ≤ j < m CD4 + RNA Pr(N2|N1c)
Pr(N2|N1c)Pr(N1c)
1∕(𝑚+1−𝑗)





























m, length of monitoring grace period in months; j, position in monitoring grace period (month)
N0: neither CD4 or RNA measured; N1: either CD4 or RNA measured but not both; N2: CD4 and RNA measured
Pr (N1c), estimated by 1 − [Pr(Nk = 1|Nk−1,Dk = 0, L̄k−1, Āk−1)]
Pr (N2| N1c), estimated by Pr(Nk = 2|Nk ≠ 1,Nk−1,Dk = 0, L̄k−1, Āk−1)
Pr (N0| N1c), equal to 1 − Pr (N2| N1c), estimated by 1 − [Pr(Nk = 2|Nk ≠ 1,Nk−1,Dk = 0, L̄k−1, Āk−1)]
Tables A1 and A2 are mathematically equivalent.
TABLE A2.2 Contribution to treatment switching weights at different time points using nested models
Type of Weight
Time Point Treatment Switch Nonstabilized Uniform Uniform w/NDE






































n, length of treatment-switching grace period in months
k, position in treatment-switching grace period (month)
A0: no switch; A1: switch to ineligible regimen; A2: switch to eligible regimen
Pr(A1c), estimated by 1 − [Pr(Ak = 1|Āk−1,Dk = 0, L̄k ,Nk)]
Pr(A2| A1c), estimated by Pr(Ak = 2|Ak ≠ 1, Āk−1,Dk = 0, L̄k ,Nk)
Pr(A0| A1c), equal to 1 − Pr (A2| A1c), estimated by 1 − [Pr(Ak = 2|Ak ≠ 1, Āk−1,Dk = 0, L̄k ,Nk)]
*Corresponds to time before the first RNA > 200 copies/ml, as well as the time in the loose-control strategies where RNA > 200
but has not yet increased above 1000 copies/ml.
APPENDIX B
EXAMPLE DATA WITHOUT THE “NO DIRECT EFFECT” ASSUMPTION
Table B1 shows data for three hypothetical individuals following each of the four joint monitoring and treatment strate-
gies over 24 months of follow-up. All three individuals had a baseline CD4 cell count of 300 cells/μl, an HIV RNA of
TABLE B1 Three hypothetical individuals following each of the four joint monitoring and treatment strategies over 24
months of follow-up
Individual Time Monitor CD4 Cell HIV RNA Switch Strategies Following*
(Months) (1: Yes, 0: No) Count Treatment(1: Yes, 0: No)
1 0 1 300 50 0 350-T, 500-T, 350-L, 500-L
1 3 0 300 50 0 350-T, 500-T, 350-L, 500-L
1 6 1 380 50 0 350-T, 500-T, 350-L, 500-L
1 9 0 380 50 0 350-T, 500-T, 350-L, 500-L
1 12 1 400 50 0 500-T, 500-L
1 15 0 400 50 0 500-T, 500-L
1 18 1 430 50 0 500-T, 500-L
1 21 0 430 50 0 500-T, 500-L
1 24 1 500 50 0 500-T, 500-L
2 0 1 300 50 0 350-T, 500-T, 350-L, 500-L
2 3 0 300 50 0 350-T, 500-T, 350-L, 500-L
2 6 1 380 500 1 350-T, 500-T
2 9 0 380 500 0 350-T, 500-T
2 12 1 400 500 0 350-T, 500-T
2 15 0 400 500 0 350-T, 500-T
2 18 1 430 100 0 350-T, 500-T
2 21 0 430 100 0 350-T, 500-T
2 24 1 500 100 0 500-T
3 0 1 300 50 0 350-T, 500-T, 350-L, 500-L
3 3 0 300 50 0 350-T, 500-T, 350-L, 500-L
3 6 1 380 500 0 350-T, 500-T, 350-L, 500-L
3 9 0 380 500 0 350-L, 500-L
3 12 1 400 1200 1 350-L, 500-L
3 15 0 400 1200 0 350-L, 500-L
3 18 1 430 500 0 350-L, 500-L
3 21 0 430 500 0 350-L, 500-L
3 24 1 500 150 0 350-L, 500-L
*350-T: threshold 350–tight control; 500-T: threshold 500–tight control; 350-L: threshold 350–loose control; 500-L: threshold 500–loose control
50 copies/ml, and were monitored every 6 months. Their CD4 cell count increased from 300 to 380, then to 400, then to
430, and, finally, to 500. The difference between the three individuals was that individual 1 never experienced virologic
failure (HIV RNA > 200 copies/ml), individual 2 experienced virologic failure at month 6 and switched treatment imme-
diately, and individual 3 experienced virologic failure at month 6 but did not switch treatment until month 12. Individual
2 achieved virologic suppression (HIV RNA ≤ 200 copies/ml) again at month 18, and individual 3 achieved virologic
suppression at month 24. Individual 1 was censored from the threshold 350 strategies at month 12 because she was mon-
itored at an interval shorter than 9-12 months while her CD4 cell count was above the 350 threshold. Individual 2 was
censored from the loose-control strategies at month 6 when she switched treatment before her HIV RNA crosses above
1000 copies/ml and was censored from the remaining 350 threshold strategy at month 24 because she was monitored at
an interval shorter than 9-12 months while her CD4 cell count was above the 350 threshold and her HIV RNA ≤ 200
copies/ml. Individual 3 was censored from the tight-control strategies at month 9 when she did not switch treatment
within 3 months of her HIV RNA crossing above 200 copies/ml.
APPENDIX C
EXAMPLE DATA WITH THE “NO DIRECT EFFECT” ASSUMPTION
Table C1.1 shows how the data for hypothetical individual 1 from Table B1 can be modified to create a “no direct effect”
data set.
First, we show individual 1’s “no direct effect” data under strategies that require individuals to be monitored exactly
every 6 months if their CD4 cell count falls below the strategy's threshold and exactly every 12 months otherwise. In the
TABLE C1.1 One hypothetical individual following all of the four joint monitoring and treatment
strategies over 24 months of follow-up under the “no direct effect” assumption, without grace periods
Time Monitor CD4 Cell “No Direct Effect” Data for “No Direct Effect” Data for
(Months) (1: Yes, 0: No) Count Threshold 350 Strategies Threshold 500 Strategies
Monitor CD4 Cell Monitor CD4 Cell
(1: Yes; 0: No) Count (1: Yes; 0: No) Count
0 1 300 1 300 1 300
1 0 300 0 300 0 300
2 0 300 0 300 0 300
3 0 300 0 300 0 300
4 0 300 0 300 0 300
5 0 300 0 300 0 300
6 1 380 1 380 1 380
7 0 380 0 380 0 380
8 0 380 0 380 0 380
9 0 380 0 380 0 380
10 0 380 0 380 0 380
11 0 380 0 380 0 380
12 1 400 0 380 1 400
13 0 400 0 380 0 400
14 0 400 0 380 0 400
15 0 400 0 380 0 400
16 0 400 0 380 0 400
17 0 400 0 380 0 400
18 1 430 1 430 1 430
19 0 430 0 430 0 430
20 0 430 0 430 0 430
21 0 430 0 430 0 430
22 0 430 0 430 0 430
23 0 430 0 430 0 430












































































































































































































































































































































































































































































































































































































































































































































































original per-protocol analysis, individual 1 was censored from the threshold 350 strategies at month 12 because she was
monitored at an interval shorter than 9-12 months while her CD4 cell count was above the 350 threshold. In the “no direct
effect” data set, we changed the observations for the two replicates following the threshold 350 strategies as follows: we (i)
recoded the monitoring indicator at month 12 to 0, (ii) discarded the CD4 cell count and HIV-RNA measurement recorded
at month 12, and (iii) carried forward the CD4 cell count and HIV RNA from month 11 until the next time the individual
was monitored at month 18. The monitoring indicator was again recoded to 0 at month 24. Monitoring is recoded to 0 at
months 12 and 24 for the replicates following the threshold 350 strategies because they are monitored sooner than indi-
cated by the strategy (every 6 months rather than every 12 months). Under the “no direct effect” assumption, individual
1 followed all four strategies for the first 24 months of follow-up. This “no direct effect” data set is shown in Table C1.1.
Note that we exclude HIV RNA from the Table for simplicity.
Table C1.2 shows the “no direct effect” data for individual 1 under strategies with grace periods (monitor every
2-7 months if CD4 is above the threshold and every 8-13 months if CD4 is below the threshold). Consider the replicate fol-
lowing the threshold 350–tight control strategy. When this replicate is monitored at month 6, during a monitoring grace
period, the replicate is split into two new replicates 16 and 26. New replicate 16 has her new CD4 cell count and HIV-RNA
measurements revealed and reenters the grace period in the usual way. This new replicate 16 is again split into two new
replicates when monitored during another monitoring grace period at month 18. New replicate 26 has her monitoring
at month 6 ignored (because she could still be monitored at month 7), moves to the next month of the monitoring grace
period, and is censored at month 7 for not being monitored at the end of the grace period. The replicate following the
threshold 350–loose control strategy is split at the same time points as the replicate following the threshold 350–tight con-
trol strategy. The two replicates following the threshold 500 strategies are split when monitored during grace periods at
months 6, 12, 18, and 24. By leveraging the grace periods and the “no direct effect” assumption, six replicates correspond-
ing to this hypothetical individual remain under follow-up at 24 months of follow-up: one follows the threshold 350–tight
control strategy, one follows the threshold 350–loose control strategy, two follow the threshold 500–tight control strategy,
and two follow-up the threshold 500–loose control strategy.
APPENDIX D
TREATMENT SWITCH
A summary of classifications of a treatment change as a nonswitch, ineligible switch, or switch is shown in Table D1, as
follows.
TABLE D1 Changes from initial eligiblea regimens to new regimens that are considered switchesb
(Center for AIDS Research Network of Integrated Clinical Systems and HIV-CAUSAL Collaboration)
Regimen Switch From Switch From Switch From Switch From
Classification (PI + ≥ 2 (bPI + ≥ 2 (NNRTI + ≥ 2 (≥ 2 NRTI +
NRTI)? NRTI)? NRTI)? FI/INSTI/EI)?
PI + ≥ 2 NRTI No No Yes Yes
bPI + ≥ 2 NRTI Yes Yes if PI changes Yes Yes
NNRTI + ≥ 2 Yes Yes Yes if NNRTI to Yes
NRTI etravirine
bPI + PI/NNRTI Yes Yes Yes if NNRTI to Yes
(+ other) etravirine
≥ 2 NRTI + Yes Yes Yes Yes if FI/INSTI/EI
FI/INSTI/EI changes or addition of a
FI/INSTI/EI
[Adapted from Cain et al, 2015]
aEligible cART regimens consist of (i) at least two nucleoside reverse transcriptase inhibitors (NRTIs) plus one
protease inhibitor (PI), (ii) at least two NRTIs plus one PI boosted with ritonavir (bPI), (iii) at least two NRTIs plus
one nonnucleoside reverse transcriptase inhibitor (NNRTI), or (iv) at least two NRTIs plus a fusion inhibitor (FI),
an integrase strand inhibitor entry (INSTI), or an entry inhibitor (EI).
bWe define a treatment switch as a change of treatment regimen to any new regimen, as described previously.8
Each treatment switch is classified as a switch to an eligible or an ineligible regimen. In the Table above, switches
to eligible regimens are labeled “Yes,” and changes in treatment that are not considered a switch are labeled “No.”
Ineligible switches include any change not outlined in this Table, such as changes to monotherapy or dual therapy
or stopping therapy all together.
